To the Editor, I want to congratulate Saraf and their colleagues [1] for their study. They retrospectively reviewed all breast cancer brain metastasis (BCBM) patients treated with brain radiotherapy from 1997 to 2015. They reported that patients with advanced high stage and triple negative breast cancer develop brain metastases significantly earlier. Interestingly, patients with Her2 positive subtype that did have documented anti-Her2 targeted therapy were excluded from the study. From this perspective, significant number of HER2 positive breast cancer patients who develop BCBM were eligible for the current study since they received anti-Her2 therapy as adjuvant and/or metastatic treatment. However, addition of anti-Her2 treatment at adjuvant or metastatic setting might delay BCBM. The efficacy of anti-Her2 therapy to control systemic disease for longer periods of time has exposed the ability of the Her2-positive breast cancer cells to develop BCBM later. In a retrospective study, patients with HER2-positive disease treated with trastuzumab had longer times to development of and better survival from BCBM compared with patients with Her2-positive disease who had never received trastuzumab [2] . Furthermore, In CLEOPATRA trial, where patients with Her2-positive first line metastatic breast cancer experienced significant improvements in progression-free and overall survival with pertuzumab, trastuzumab and docetaxel compared with placebo, trastuzumab and docetaxel [3] . In this trial, an exploratory analysis of the incidence and time to development of * Kadri Altundag altundag66@yahoo.com 1 MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey
